Mölnlycke integrated Annual Report 2023
Today we are delighted to announce the launch of the Mölnlycke integrated Annual Report 2023. Our dedication to revolutionising care for people and planet contributed to a very successful year with record high annual net sales of EUR 1,924 million and substantial improvements in profitability. We continue to report our sustainability achievements in accordance with the Global Reporting Initiative (GRI) standards.
Performance highlights
Mölnlycke reported strong growth in 2023, with net sales reaching EUR 1,924 million, an 8% increase in constant currency rates. The EBITDA grew by 14% to EUR 545 million, reflecting substantial organic growth and market share gains across most markets.
Sustainability achievements
We made significant strides in operationalising our sustainability roadmap 2030. Mölnlycke’s near-term greenhouse gas emission reduction targets were validated by the Science Based Targets initiative. Noteworthy progress was made in our journey towards 100% fossil-free electricity by the end of 2024, with 61% fossil-free electricity share in 2023. We also achieved a 20% reduction in overall absolute greenhouse gas emissions across the entire value chain compared to the 2021 baseline. Finally, we expanded the scope of Life Cycle Assessment to cover 30% of our portfolio in terms of net sales.
"In 2023 we continued to execute on a strategy firmly rooted in customer research and pivoted to lead in sustainable, digital and customer-centric healthcare. With strong growth and substantial improvements in profitability, I am confident that we are on the right track".
Zlatko Rihter Chief Executive Officer
Innovation and quality highlights
To enhance surgical performance, Mölnlycke introduced hand scanning technology using artificial intelligence and machine learning for optimal glove fit, launched Mepilex® Up in the US, upgraded the Mepilex® Border Post-Op product family globally and registered Hibiwash®, - the new colour- and fragrance-free Hibi formula. We also successfully completed the transition to Medical Device Regulation (MDR), one of the first MedTech companies to do so.
Strategic investments
Mölnlycke secured long-term financing through a EUR 400 million Eurobond and a EUR 350 million Revolving Credit Facility. We also decided to invest EUR 60 million to increase production capacity, including a new Mepilex Border Flex production line and a new Ethylene Oxide sterilisation unit in Finland.
Latest news
-
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.
-
Europe faces a growing chronic wound crisis – time to act is now
Gothenburg, Sweden. 31 March 2026. Mölnlycke®, a global leader in MedTech, today welcomes the publication of Shaping the future of wound care in Europe, the first joint industry white paper from the MedTech Europe Wound Care Sector Working Group. The wound paper highlights the growing burden of chronic wounds and urges EU policymakers to elevate wound care as a strategic health priority across the EU.
-
Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.
-
Mölnlycke joins National Climate Initiative within healthcare and life science
A broad public–private partnership is now being launched to accelerate the green transition within the Swedish healthcare and life science sector. The initiative aims, through collaboration, to reduce greenhouse gas emissions with the ambition of reaching net zero across the entire value chain by 2045.
-
Mölnlycke® celebrates 100 million ProcedurePak® trays - advancing operating room efficiency worldwide
Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in Medtech, headquarted in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company's production sites in the Czech Republic.
-
Making sustainable healthcare work
Healthcare systems worldwide are under pressure to deliver more with less. Fewer resources, tighter budgets, and growing demands. In this article, published in Clinical Services Journal, Eric De Kesel, Chief Operating Officer & Executive Vice President Sustainability and Dr Emma Wright, Chief Medical Officer at Mölnlycke Health Care, explain how Mölnlycke is turning sustainable healthcare from aspiration into practice by connecting performance, people, and planet.
-
Clinician wellbeing is key to sustainable healthcare
Clinician wellbeing is the cornerstone of sustainable healthcare. Dr Emma Wright, Chief Medical Officer at Mölnlycke Health Care, explains why supporting those who deliver care is essential and how value-based healthcare can unlock better outcomes for patients, healthcare professionals, and healthcare systems.
-
Mölnlycke recognised with EUPD’s ‘ESG Transparency Award
We are delighted to announce that Mölnlycke was recognised with ‘ESG Transparency Award' by EUPD Research. Mölnlycke achieved the highest excellence level with the total score of 95,5%.
-
Shaping wound care policy across Europe
We are proud to play our part in shaping the future of wound care in Europe. Mölnlycke has been elected one of the organisations leading the Wound Care Sector Working Group at MedTech Europe, the industry association representing medical technology across the continent.